Browsing by Author Kirito, Keita

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 5 of 5
TitleAuthor(s)Issue Date
 
Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance
Journal:JCO Oncology Practice
Kirito, KeitaChoi, Chul WonHein, ThanHou, Hsin-AnJung, Chul WonKwong, Yok-LamLeung, Garret MKOoi, Melissa GMRojnuckarin, PonlapatRoss, David MShih, Lee-YungTakenaka, KatsutoTeo, Winnie ZYGill, Harinder
17-Jul-2025
 
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms
Journal:Current Hematologic Malignancy Reports
Bose, PrithvirajXiao, ZhijianHasselbalch, Hans C.Prchal, Josef T.Duan, MinghuiYacoub, AbdulraheemRampal, RaajitKiladjian, Jean-JacquesHobbs, Gabriela S.Tashi, TsewangShimoda, KazuyaKirito, KeitaGill, HarinderHou, Hsin-AnLee, Sung-EunHuang, JianLi, BingQin, AlbertYu, Lennex Hsueh-LinMascarenhas, John O.Mesa, Ruben A.
12-Jul-2025
 
Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)
Journal:Blood
Gill, HarinderChoi, Chul WonThan, HeinHou, Hsin-AnJung, Chul WonKwong, Yok-LamLeung, Garret M KOoi, Melissa G MRojnuckarin, PonlapatRoss, David MShih, Lee-YungTakenaka, KatsutoTeo, Winnie Z YKirito, Keita
5-Nov-2024
 
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
Journal:The Lancet Haematology
Mesa, RubenGill, HarinderZhang, LeiJin, JieKirito, KeitaKomatsu, NorioQin, AlbertXiao, ZhijianTashi, TsewangShimoda, KazuyaOhishi, KohshiChen, SuningZuo, XuelanShirane, ShuichiHu, YuZhang, SujiangWang, YiTakenaka, KatsutoIchii, MichikoXu, NaShih, Lee-YungLim, Ken-HongLee, Sung-EunBae, Sung HwaTeo, Winnie Z YMaze, DawnOh, Stephen TBose, PrithvirajSato, ToshiakiZagrijtschuk, OlehLin, SheenaShih, Weichung JoeMascarenhas, JohnMasarova, Lucia
1-Nov-2025
 
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial
Journal:Journal of Clinical Oncology
Mesa, Ruben AGill, HarinderXiao, ZhijianKomatsu, NorioQin, AlbertTashi, TsewangZhang, LeiJin, JieKirito, KeitaOhishi, KohshiShirane, ShuichiShih, Lee-YungLee, Sung-EunTeo, Winnie ZYMaze, DawnOh, StephenSato, ToshiakiShih, WeichungMascarenhas, JohnMasarova, LuciaSURPASS-ET Study Group
1-Jun-2025
Showing results 1 to 5 of 5